CANbridge Pharmaceuticals Inc. (1228.HK)

0,335 -0,010 (-2,90%) Al cierre: 03:59PM HKT

CANbridge Pharmaceuticals Inc.

Unit 18, 6th Floor
Building 21 No. 388 Xinping Street Suzhou Industrial Park
Suzhou
China
86 10 8414 8018
https://www.canbridgepharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 100

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. James Qun Xue M.B.A., Ph.D.	Founder, Chairman of the Board, CEO & Member of Strategic Advisory Board	6,32M	N/A	1970
Mr. Glenn Hassan	Chief Financial Officer	N/A	N/A	1979
Dr. Pauline Li M.B.A., M.D.	Senior VP of Clinical Development & Operations	N/A	N/A	N/A
Ms. Qian Ma	Director of Legal & Compliance, Board Secretary and Joint Company Secretary	N/A	N/A	N/A
Ms. Stella Mao	Senior Director of Public Affairs	N/A	N/A	N/A
Ms. Chris Chen	Vice President of Human Resources	N/A	N/A	N/A
Dr. Gerald F. Cox M.D., Ph.D.	Chief Development Strategist & Interim Chief Medical Officer	N/A	N/A	1959
Mr. Marcelo Cheresky	Chief Commercial Officer	N/A	N/A	1966
Dr. Wei Zhang	Senior Director & Head of CMC China	N/A	N/A	N/A
Ms. Rebecca Zhang	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en HKD.

Descripción

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. CANbridge Pharmaceuticals Inc. was founded in 2012 and is headquartered in Suzhou, China.

Gobierno corporativo

El ISS Governance QualityScore de CANbridge Pharmaceuticals Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.